2024
BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
O’Connor C, Asfour L, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Meah N, Ohyama M, Ovcharenko J, Primez R, Piraccini B, Rudnicka L, Corralo D, Shapiro J, Sinclair R, Smith B, Starace M, Galvan S, Wang K, York K, McDonald I, Wall D. BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists. British Journal Of Dermatology 2024, 191: i74-i75. DOI: 10.1093/bjd/ljae090.151.Peer-Reviewed Original ResearchLiver function testsFunction testsHIV testingHepatitis BLipid testingAlopecia areataSeverity of Alopecia ToolScreening bloodHair disordersRenal function testsRisk of cardiovascular diseaseJanus kinase inhibitorsDermatology Life Quality IndexJanus kinaseBritish Association of DermatologistsLife Quality IndexLaboratory testsHair loss disorderSystemic therapyThyroid testsIdentification of comorbiditiesImmune-mediatedRenal functionThyroid diseaseAssociation of DermatologistsImprovement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Craiglow B, Lee Y, Vañó-Galván S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen Y, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatology And Therapy 2024, 1-10. PMID: 38904749, DOI: 10.1007/s13555-024-01208-x.Peer-Reviewed Original ResearchSymptoms of anxietyQuality of lifeDomain scoresHealth-related quality of lifeMeasures of quality of lifeMeasures of HRQoLHealth-related qualityBaricitinib 2 mgSALT scoreBaricitinib 4 mgPsychosocial distressAssociated with improvementsHair regrowthAA scaleMethodsThis post hoc analysisHRQoLDose of baricitinibInterquartile rangePhase III trialsResultsIn totalSevere alopecia areataPost hoc analysisDisease associated with high ratesDepressionScoresThe Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease durationIn‐person validation of the Ichthyosis Scoring System
Echeandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.Peer-Reviewed Original ResearchInterrater intraclass correlation coefficientsIntrarater reliabilityIn-personIntraclass correlation coefficientIn-person evaluationContent validityInterrater reliabilityHeterogeneous group of skin disordersGroup of skin disordersIntraraterMedical professionalsInterrater agreementErythema evaluationIchthyosis subtypesPhotographic evaluationErythema scoreInterraterErythemaQuantify severitySkin disordersClinical utilityIchthyosisScoring systemHeterogeneous groupCorrelation coefficient
2023
Efficacité dans les sous-groupes liée aux caractéristiques de la maladie de patients atteints de pelade dans les études BRAVE-AA1 et BRAVE-AA2
Mayo T, Taylor S, Ito T, Vañó-Galván S, Ball S, Lu N, Chiasserini C, Chen Y, Craiglow B, Leveque C. Efficacité dans les sous-groupes liée aux caractéristiques de la maladie de patients atteints de pelade dans les études BRAVE-AA1 et BRAVE-AA2. Annales De Dermatologie Et De Vénéréologie - FMC 2023, 3: a336. DOI: 10.1016/j.fander.2023.09.579.Peer-Reviewed Original ResearchImprovement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. JEADV Clinical Practice 2023, 3: 242-248. DOI: 10.1002/jvc2.269.Peer-Reviewed Original ResearchSevere alopecia areataSymptoms of anxietyHealth-related qualityAlopecia areataWeek 36Hair regrowthAutoimmune hair loss disorderPsychological burdenBackground Alopecia areataProportion of patientsPhase 3 trialSelective Janus kinase 1JAK-2 inhibitorHair loss disorderBaricitinib 2Nonresponder imputationMethods PatientsHADS scoresMore patientsLarge trialsHospital AnxietyDepression ScaleAA symptomsPsychosocial distressAnalysis of covariance
2022
502 The genomic and phenotypic landscape of ichthyosis: An analysis of 1000 kindreds
Sun Q, Marukian N, Cheraghlou S, Paller A, Larralde M, Bercovitch L, Levinsohn J, Ren I, Hu R, Zhou J, Zaki T, Fan R, Tian C, Saraceni C, Nelson-Williams C, Loring E, Craiglow B, Milstone L, Lifton R, Boyden L, Choate K. 502 The genomic and phenotypic landscape of ichthyosis: An analysis of 1000 kindreds. Journal Of Investigative Dermatology 2022, 142: s85. DOI: 10.1016/j.jid.2022.05.511.Peer-Reviewed Original Research
2019
Review of genodermatoses with characteristic histopathology and potential diagnostic delay
Ko CJ, Atzmony L, Lim Y, McNiff JM, Craiglow B, Antaya RJ, Choate KA. Review of genodermatoses with characteristic histopathology and potential diagnostic delay. Journal Of Cutaneous Pathology 2019, 46: 756-765. PMID: 31148225, DOI: 10.1111/cup.13520.Peer-Reviewed Original Research
2018
379 Quality of life in children with ichthyosis
Olamiju B, Ren I, Li L, Deng Y, Marukian N, Zhou J, Hu R, Zaki T, Craiglow B, Choate K. 379 Quality of life in children with ichthyosis. Journal Of Investigative Dermatology 2018, 138: s64. DOI: 10.1016/j.jid.2018.03.385.Peer-Reviewed Original Research
2017
291 Establishing and validating an ichthyosis severity index
Marukian N, Deng Y, Gan G, Ren I, Thermidor W, Craiglow B, Milstone L, Choate K. 291 Establishing and validating an ichthyosis severity index. Journal Of Investigative Dermatology 2017, 137: s50. DOI: 10.1016/j.jid.2017.02.307.Peer-Reviewed Original Research458 Cellular and metabolic basis for the ichthyotic phenotype in ichthyin deficiency
Mauldin E, Cassal M, Jeong S, Vavrova K, Uchida Y, Park K, Craiglow B, Choate K, Shin K, Lee Y, Khnykin D, Grove G, Elias P. 458 Cellular and metabolic basis for the ichthyotic phenotype in ichthyin deficiency. Journal Of Investigative Dermatology 2017, 137: s79. DOI: 10.1016/j.jid.2017.02.477.Peer-Reviewed Original Research
2016
383 A novel erythrokeratodermia-cardiomyopathy syndrome is caused by dominant, clustered mutations in desmoplakin
Boyden L, Kam C, Hernández-Martín A, Zhou J, Craiglow B, Milstone L, Hu R, Elias P, Green K, Choate K. 383 A novel erythrokeratodermia-cardiomyopathy syndrome is caused by dominant, clustered mutations in desmoplakin. Journal Of Investigative Dermatology 2016, 136: s68. DOI: 10.1016/j.jid.2016.02.416.Peer-Reviewed Original Research
2014
Dominant De Novo Mutations in GJA1 Cause Erythrokeratodermia Variabilis et Progressiva, without Features of Oculodentodigital Dysplasia
Boyden LM, Craiglow BG, Zhou J, Hu R, Loring EC, Morel KD, Lauren CT, Lifton RP, Bilguvar K, , Paller A, Choate K. Dominant De Novo Mutations in GJA1 Cause Erythrokeratodermia Variabilis et Progressiva, without Features of Oculodentodigital Dysplasia. Journal Of Investigative Dermatology 2014, 135: 1540-1547. PMID: 25398053, PMCID: PMC4430428, DOI: 10.1038/jid.2014.485.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceCell MembraneChildChild, PreschoolConnexin 43ConnexinsCraniofacial AbnormalitiesDisease ProgressionErythrokeratodermia VariabilisExomeEye AbnormalitiesFemaleFoot Deformities, CongenitalGolgi ApparatusHeLa CellsHumansImmunohistochemistryMaleMolecular Sequence DataMutagenesis, Site-DirectedMutationPhenotypeSequence Analysis, DNASequence Homology, Amino AcidSkin DiseasesSyndactylyTooth AbnormalitiesConceptsSkin diseasesGJA1 mutationsErythrokeratodermia variabilis et progressivaOculodentodigital dysplasiaProgressive skin diseaseDe novo missense mutationsNovo missense mutationCutaneous findingsDominant de novo mutationsSkin disordersGap junction proteinDe novo mutationsBarrier functionConnexin 43Exome sequencingJunction proteinsPalmoplantar keratodermaDysplasiaGJA1Novo mutationsDiseaseMissense mutationsDifferent mutationsEpidermal homeostasisMembrane localizationKilling Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
Craiglow BG, King BA. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis. Journal Of Investigative Dermatology 2014, 134: 2988-2990. PMID: 24940651, DOI: 10.1038/jid.2014.260.Peer-Reviewed Original Research
2013
Somatic HRAS p.G12S Mutation Causes Woolly Hair and Epidermal Nevi
Levinsohn JL, Teng J, Craiglow BG, Loring EC, Burrow TA, Mane SS, Overton JD, Lifton RP, McNiff JM, Lucky AW, Choate KA. Somatic HRAS p.G12S Mutation Causes Woolly Hair and Epidermal Nevi. Journal Of Investigative Dermatology 2013, 134: 1149-1152. PMID: 24129065, PMCID: PMC3961553, DOI: 10.1038/jid.2013.430.Peer-Reviewed Original ResearchTopical Tazarotene for the Treatment of Ectropion in Ichthyosis
Craiglow BG, Choate KA, Milstone LM. Topical Tazarotene for the Treatment of Ectropion in Ichthyosis. JAMA Dermatology 2013, 149: 598-600. PMID: 23677086, PMCID: PMC3809825, DOI: 10.1001/jamadermatol.2013.239.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment of ectropionTopical tazaroteneBilateral lower eyelid ectropionGroup of patientsStandard of carePotential treatment optionLower eyelid ectropionPotential effective treatmentTopical retinoidsMedical therapySurgical interventionTreatment optionsEyelid ectropionCosmetic consequencesEffective treatmentCertain subtypesPatientsEctropionPersistent improvementDaily applicationTazaroteneAdditional studiesAdverse effectsRetinoidsIchthyosisTwo Cases of Hemihyperplasia–Multiple Lipomatosis Syndrome and Review of Asymmetric Hemihyperplasia Syndromes
Craiglow BG, Ko CJ, Antaya RJ. Two Cases of Hemihyperplasia–Multiple Lipomatosis Syndrome and Review of Asymmetric Hemihyperplasia Syndromes. Pediatric Dermatology 2013, 31: 507-510. PMID: 23458125, DOI: 10.1111/pde.12071.Peer-Reviewed Original ResearchManagement of Infantile Hemangiomas
Craiglow BG, Antaya RJ. Management of Infantile Hemangiomas. Pediatric Drugs 2013, 15: 133-138. PMID: 23456550, DOI: 10.1007/s40272-013-0008-6.Peer-Reviewed Original ResearchConceptsAdditional new therapiesTreatment of IHPotential pharmacotherapeutic approachBenign vascular neoplasmMost IHsOral propranololSuperficial IHsTopical timololMedical therapyCommon tumorsPharmacotherapeutic approachesVascular neoplasmInfantile hemangiomasNew therapiesSignificant disfigurementNew treatmentsVital structuresHemangiomaTreatmentTherapyIHCorticosteroidsImiquimodUlcerationNeoplasmsIchthyosis in the newborn
Craiglow BG. Ichthyosis in the newborn. Seminars In Perinatology 2013, 37: 26-31. PMID: 23419760, PMCID: PMC3758581, DOI: 10.1053/j.semperi.2012.11.001.Peer-Reviewed Original Research
2008
Pediatric dermatology workforce shortage: Perspectives from academia
Craiglow BG, Resneck JS, Lucky AW, Sidbury R, Yan AC, Resnick SD, Antaya RJ. Pediatric dermatology workforce shortage: Perspectives from academia. Journal Of The American Academy Of Dermatology 2008, 59: 986-989. PMID: 18835061, DOI: 10.1016/j.jaad.2008.08.036.Peer-Reviewed Original Research